Health Canada makes Tetra Bio-Pharma cannabis-delivery product a Class Two medical device.

A Health Canada decision to reclassify, to a Class Two medical device, Tetra Bio-Pharma’s inhalation pipe for cannabis medication means that patients suffering cancer pain may soon be able to claim the cost of the device through their private and public-insurance plans, the company announced today.

Tetra is a developing several cannabis drugs.

A current phase 3 trial to treat cancer pain aims to improve patients’ quality of life and reduce pain for those in the late-stage of the disease.

The company’s CEO and chief scientific officer said the Government of Canada’s decision is an important step forward in facilitating access to cannabis drugs.

“We believe it will provide patients with a financial benefit in terms of coverage for the device and prescription drug,” said Dr. Chamberland, “as many cancer patients rely on private and public insurance plans for access to the medication. 

The number of Canadians using medical cannabis is expected to grow from the 300,000 current registered to use the medication.

Dr. Chamberland said the lack of scientific data on the safety and efficacy of cannabis is “a critical barrier to patient access and something Canadian physicians are waiting for before being comfortable prescribing it.”

The company recently announced it is starting a trial to investigate cannabis versus Fentanyl in managing breakthrough cancer pain.

“Coupled with our robust clinical trial program and the evidence we are establishing (this) will support physicians in discussing and recommending this option with their patients,” he said.

The company has also signed a deal  with Genacol Canada to get Tetra’s oral capsule and a topical cream into the $2.5-billion market for joint-pain-and inflammation products.

A subsequent CBD supply agreement with True North Cannabis will provide Tetra with high-quality, competitively priced CBD.

The new agreements build on the company’s strong position as a leader in discovering, developing and commercializing  products derived from cannabinoids.

Safety and pharmacokinetic studies in healthy volunteers is providing information on proper dosing and a clear understanding of the potential cardiovascular and neurological risks to patients.

“This information is critical to protect public health, and Tetra Bio-Pharma is engaged with Health Canada to comply with the highest drug safety standards,” the company said.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s